The Magpie Trial: Long-term Effects of Magnesium Sulphate for Pre-eclampsia
Author Information
Author(s): Magpie Trial Follow-Up Study Collaborative Group
Primary Institution: Nuffield Department of Medicine, University of Oxford
Hypothesis
Does magnesium sulphate for pre-eclampsia affect long-term health outcomes for women?
Conclusion
Magnesium sulphate use for pre-eclampsia does not lead to increased death or disability in women after 2 years.
Supporting Evidence
- 3.5% of women allocated magnesium sulphate experienced death or serious morbidity related to pre-eclampsia.
- 4.2% of women allocated placebo experienced death or serious morbidity related to pre-eclampsia.
- The relative risk of serious morbidity was 0.84 for magnesium sulphate compared to placebo.
Takeaway
This study looked at women who had pre-eclampsia and found that using magnesium sulphate didn't cause more problems for them later on.
Methodology
Women were assessed through questionnaires and interviews 2-3 years after delivery.
Potential Biases
Bias in outcome assessment is unlikely as it was conducted blind to treatment allocation.
Limitations
Some women were not contacted for follow-up, and the study may underestimate true morbidity.
Participant Demographics
Women from 125 centres in 19 countries, with varying perinatal mortality rates.
Statistical Information
P-Value
0.84
Confidence Interval
0.60–1.18
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website